Novartis, Zurich University Spin-out Anaveon Tackles IL-2 Challenges With Fresh Funds

 
• By Eleanor Malone

Syncona and Novartis Venture Fund have invested CHF35m in Anaveon, which reckons it can overcome the toxicity and half-life limitations of the cytokine interleukin-2 to enhance the body’s immune response to tumors.

Boyman_Onur
Andreas Katopodis (l) and Onur Boyman (r) • Source: Shutterstock

More from Financing

More from Business